News in a nutshell

Pharma research jobs on the chopping blockAnnouncements of job loss in big pharma continue, with the UK press saying that GlaxoSmithKline will soon announce 4,000 layoffs, nearly half in R&D. linkurl:(The Guardian);http://business.timesonline.co.uk/tol/business/industry_sectors/health/article7010418.ece AstraZeneca said last week it would cut 8000 jobs, 3,500 of them in R&D, and noted plans to outsource more of its research and trim the number of disease areas on which the company focuses. linku

Written byAlla Katsnelson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Pharma research jobs on the chopping block
Announcements of job loss in big pharma continue, with the UK press saying that GlaxoSmithKline will soon announce 4,000 layoffs, nearly half in R&D. linkurl:(The Guardian);http://business.timesonline.co.uk/tol/business/industry_sectors/health/article7010418.ece AstraZeneca said last week it would cut 8000 jobs, 3,500 of them in R&D, and noted plans to outsource more of its research and trim the number of disease areas on which the company focuses. linkurl:(Wall Street Journal Health Blog);http://blogs.wsj.com/health/2010/01/28/astrazeneca-to-cut-another-8000-jobs/
Image: Wikipedia
FDA slaps doc for skin treatment statements
In a rare case of the agency censuring an individual rather than a company, the US Food and Drug Administration issued a warning letter to Miami Beach clinical researcher and dermatologist Leslie Baumann for "expressing premature enthusiasm" over a not-yet-approved injectible anti-wrinkle drug, the New York Times linkurl:reports.;http://www.nytimes.com/2010/02/01/business/01wrinkle.html?ref=health The linkurl:letter,;http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM198400.pdf issued last month, says Baumann improperly promoted the drug in statements to the media in 2007. Stem cells: an approval and some grants
NIH director Francis Collins has ok'ed linkurl:an advisory council's recommendation;http://www.the-scientist.com/blog/display/57093/ to include one of the most commonly used embryonic stem cell lines, developed by Wisconsin researchers, in the linkurl:federal registry;http://grants.nih.gov/stem_cells/registry/current.htm?id=29 of embryonic stem cell lines. Meanwhile, the California Institute for Regenerative Medicine announced linkurl:a new round of grants;http://www.cirm.ca.gov/files/meetings/pdf/2010/%23%208%20for%202_3-4_10%20ICOC_RFA10-02%20TT2%20Concept%20Proposal%20012710.pdf for developing "tools and technologies for translational bottlenecks" -- including "disease in a dish" models. Researchers in both academia and industry are eligible to apply, the linkurl:California Stem Cell Report;http://californiastemcellreport.blogspot.com/2010/01/cirm-proposes-40-million-stem-cell.html notes. A homeopathy protest
A society of skeptics in the UK this weekend staged a mass overdose of homeopathy therapies to show that such treatments don't work. They staged their treat-ins outside of branches of the major UK pharmacy chain Boots -- which sells homeopathic medicines -- in a handful of cities. The group said similar demonstrations were planned for Canada, Spain, the US, and Australia, linkurl:The Independent reports.;http://www.independent.co.uk/life-style/health-and-families/health-news/mass-overdose-staged-in-homeopathic-protest-1884019.html PhD thesis, anyone?
Finally, PhD supervisors and PhD students -- check out linkurl:this guide;http://www.timeshighereducation.co.uk/story.asp?sectioncode=26&storycode=410208&c=1 to how not to write a PhD thesis. This one isn't specific to the life sciences, but we'd say the key points apply. Our favorite no-no: "Assume something you are doing is new because you have not read enough to know that an academic wrote a book on it 20 years ago."
**__Related stories:__*** linkurl:Right your writing;http://www.the-scientist.com/article/display/56104/
[November 2009]*linkurl:Research loss in Pfizer-Wyeth deal;http://www.the-scientist.com/blog/display/56063/
[16th Octoberm 2009]*linkurl:Profiting from pluripotency;http://www.the-scientist.com/2009/02/1/60/1/
[February 2009]*
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform